Form 8-K - Current report:
SEC Accession No. 0001773427-24-000016
Filing Date
2024-05-02
Accepted
2024-05-02 06:29:46
Documents
15
Period of Report
2024-05-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K swtx-20240502.htm   iXBRL 8-K 29212
2 EX-99.1 swtx-20240331xearningsrele.htm EX-99.1 61057
6 GRAPHIC springworkslogoq12022.jpg GRAPHIC 7112
  Complete submission text file 0001773427-24-000016.txt   234485

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT swtx-20240502.xsd EX-101.SCH 1907
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT swtx-20240502_lab.xml EX-101.LAB 21594
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT swtx-20240502_pre.xml EX-101.PRE 12512
18 EXTRACTED XBRL INSTANCE DOCUMENT swtx-20240502_htm.xml XML 2929
Mailing Address 100 WASHINGTON BOULEVARD STAMFORD CT 06902
Business Address 100 WASHINGTON BOULEVARD STAMFORD CT 06902 203-883-9490
SpringWorks Therapeutics, Inc. (Filer) CIK: 0001773427 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39044 | Film No.: 24905088
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)